

Int'l Appl. No.
Filed

PCT/BE99/00112
August 17, 1999

[nucleotide sequence]polynucleotide encoding a peptide of the ONECUT family, a vector comprising [this nucleotide sequence]said polynucleotide, the polypeptide [sequence] encoded by [this nucleotide sequence]said polynucleotide and/or] a cell line transformed with said vector [and expressing the peptide of the ONECUT family].

2. (Amended) The pharmaceutical composition [as claimed in]of claim 1, [characterized in that]wherein the protein of the ONECUT family is an isoform of HNF-6 [in its two isoforms].

3. (Amended) The pharmaceutical composition [as claimed in]of claim 1, [characterized in that]wherein the protein of the ONECUT family is OC-2, the amino acid sequence of which is SEQ ID No. 2.

4. (Amended) The [cellular] pharmaceutical composition [as claimed in]of claim 1, [characterized in that]wherein the protein of the ONECUT family is OC-3, the amino acid sequence of which is SEQ ID No 3.

5. (Amended) The pharmaceutical composition [as claimed in any one of the preceding claims, characterized in that]of Claim 1, wherein said [nucleotide and polypeptide sequences are]polynucleotide is a human polynucleotide[nucleotide and polypeptide sequence].

6. (Amended) The pharmaceutical composition [as claimed in any one of the preceding claims, characterized in that]of Claim 1, wherein the vector is [chosen]selected from the group consisting of plasmids, viruses, phagemids, lipid vesicles, in particular cationic vesicles, liposomes [or]and a mixture [of these]thereof.

7. (Amended) [The use of the pharmaceutical composition as claimed in any one of the preceding claims, for preparing a medicinal product intended]A method for the prevention and/or for the treatment of type 1 or type 2 diabetes or of disorders linked to diabetes, for the prevention and/or for the treatment of cancer[, in particular of melanoma,] and for the prevention and for the treatment of Waardenburg syndrome, comprising:
administration of the pharmaceutical composition of Claim 1 in an amount effective to prevent or reduce the symptoms of diabetes, cancer, and/or Waardenburg syndrome.

8. (Amended) [A]The method of [therapeutic treatment of a patient, preferably of a human patient, likely to develop or suffering from diabetes, from a cancer, in particular from a melanoma, or from Waardenburg syndrome, characterized in that]Claim 7, wherein